The blood pressure lowering effects of glucagon-like peptide-1 receptor agonists: A mini-review of the mechanisms

Author(s)

Ribeiro-Silva, Joao Carlos ; Tavares, Caio A. M. ; Girardi, Adriana C. C.

• Document type: Journal article
• Source: CURRENT OPINION IN PHARMACOLOGY; v. 69, p. 9-pg., 2023-02-28.

Abstract

The incretin hormone glucagon-like peptide 1 (GLP-1) is a key component of the signaling mechanisms promoting glucose homeostasis. Clinical and experimental studies demonstrated that GLP-1 receptor agonists, including GLP-1 itself, have favorable effects on blood pressure and reduce the risk of major cardiovascular events, independently of their effect on glycemic control. GLP-1 receptors are present in the hypo-thalamus and brainstem, the carotid body, the vasculature, and the kidneys. These organs are involved in blood pressure regulation, have their function altered in hypertension, and are positively benefited by the treatment with GLP-1 receptor ag-onists. Here, we discuss the potential mechanisms whereby activation of GLP-1R signaling exerts blood pressure-lowering effects beyond glycemic control. (AU)

• FAPESP's process: 16/22140-7 - Molecular bases of renal tubular function and dysfunction
• Grantee: Adriana Castello Costa Girardi
• Support Opportunities: Research Projects - Thematic Grants
• FAPESP's process: 21/14534-3 - Pleiotropic effects of antidiabetic agents and their pharmacological targets: renoprotective mechanisms beyond glycemic control
• Grantee: Adriana Castello Costa Girardi
• Support Opportunities: Research Projects - Thematic Grants